Targeting the Wnt/β-catenin signaling pathway in cancer
By Ya Zhang, Xin Wang. Journal of Hematology & Oncology, 2020
1,182 citations recorded by the source corpus.
The aberrant Wnt/β-catenin signaling pathway facilitates cancer stem cell renewal, cell proliferation and differentiation, thus exerting crucial roles in tumorigenesis and therapy response. Accumulated investigations highlight the therapeutic potential of agents targeting Wnt/β-catenin signaling in cancer. Wnt ligand/ receptor interface, β-catenin destruction complex and TCF/β-catenin transcription complex are key components of the cascade and have been targeted with interventions in preclinical and clinical evaluations. This scoping review aims at outlining the latest progress on the current approaches and perspectives of Wnt/β-catenin signaling pathway targeted therapy in various cancer types. Better understanding of the updates on the inhibitors, antagonists and activators of Wnt/β-catenin pathway rationalizes innovative strategies for personalized cancer treatment. Further investigations are warranted to confirm precise and secure targeted agents and achieve optimal use with clinical benefits in malignant diseases.
Subfields: Molecular Biology
View Paper: https://www.semanticscholar.org/paper/0d7942a68a143e7bb071bb09cce214062907f1cc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Haibo Xu
- Maolun Liu
- Shan Ren
- Han Yang
- Tianqi Ming
- Shunlei Tang
- Qiu Tao
- Hui-Ying Zhao
Citations in the corpus
- Wnt signaling in colorectal cancer: pathogenic role and therapeutic target (2022, background): “The Wnt ligand/receptor interface, β-catenin destruction complex, and TCF/βcatenin transcription complex are key components of the cascade and have become targets for preclinical and clinical evaluation interventions [14].”